» Articles » PMID: 18609687

Inflammatory Bowel Disease in Rats: Bacterial and Chemical Interaction

Overview
Specialty Gastroenterology
Date 2008 Jul 9
PMID 18609687
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To develop a novel model of colitis in rats, using a combination of iodoacetamide and enteropathogenic E. coli (EPEC), and to elucidate the pathophysiologic processes implicated in the development of ulcerative colitis (UC).

Methods: Male Sprague-Dawley rats (n = 158) were inoculated intrarectally on a weekly basis with 4 different combinations: (a) 1% methylcellulose (MC), (b) 100 microL of 6% iodoacetamide (IA) in 1% MC, (c) 200 microL containing 4 x 10(8) colony factor units (CFU) of EPEC, and (d) combined treatment of (IA) followed by bacteria (B) after 2 d. Thirty days post treatment, each of the four groups was divided into two subgroups; the inoculation was stopped for one subgroup and the other subgroup continued with biweekly inoculation until the end of the experiment. Colitis was evaluated by the clinical course of the disease, the macroscopic and microscopic alterations, activity of myeloperoxidase (MPO), and by TNF-alpha gene expression.

Results: Findings indicative of UC were seen in the combined treatment (IA + B) as well as the IA continued treatment groups: the animals showed slow rate of increase in body weight, diarrhea, bloody stools, high colonic ulcer score, as well as histological alterations characteristic of UC, with an extensive inflammatory reaction. During the course of the experiment, the MPO activity was consistently elevated and the TNF-alpha gene expression was upregulated compared to the control animals.

Conclusion: The experimental ulcerative colitis model used in the present study resembles, to a great extent, the human disease. It is reproducible with characteristics indicative of chronicity.

Citing Articles

Probiotic Bacillus licheniformis MCC2514 and Bifidobacterium breve NCIM 5671 Regulates GATA3 and Foxp3 Expression in the Elevated Disease Condition.

Rohith H, Peddha M, Halami P Probiotics Antimicrob Proteins. 2023; 16(3):894-910.

PMID: 37195508 DOI: 10.1007/s12602-023-10080-8.


Metformin and Probiotics in the Crosstalk between Colitis-Associated Colorectal Cancer and Diabetes in Mice.

Al Kattar S, Jurjus R, Pinon A, Leger D, Jurjus A, Boukarim C Cancers (Basel). 2020; 12(7).

PMID: 32664279 PMC: 7408863. DOI: 10.3390/cancers12071857.


Characterization of Rat ILCs Reveals ILC2 as the Dominant Intestinal Subset.

Abidi A, Laurent T, Beriou G, Bouchet-Delbos L, Fourgeux C, Louvet C Front Immunol. 2020; 11:255.

PMID: 32140157 PMC: 7043102. DOI: 10.3389/fimmu.2020.00255.


A novel therapeutic approach to colorectal cancer in diabetes: role of metformin and rapamycin.

Gerges Geagea A, Rizzo M, Jurjus A, Cappello F, Leone A, Tomasello G Oncotarget. 2019; 10(13):1284-1305.

PMID: 30863490 PMC: 6407684. DOI: 10.18632/oncotarget.26641.


Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links.

Jurjus A, Eid A, Al Kattar S, Zeenny M, Gerges-Geagea A, Haydar H BBA Clin. 2016; 5:16-24.

PMID: 27051585 PMC: 4802401. DOI: 10.1016/j.bbacli.2015.11.002.


References
1.
Farrell R, Peppercorn M . Ulcerative colitis. Lancet. 2002; 359(9303):331-40. DOI: 10.1016/S0140-6736(02)07499-8. View

2.
Perez-Navarro R, Ballester I, Zarzuelo A, Sanchez de Medina F . Disturbances in epithelial ionic secretion in different experimental models of colitis. Life Sci. 2005; 76(13):1489-501. DOI: 10.1016/j.lfs.2004.09.019. View

3.
Jurjus A, Barada K, Khoury N, Assef M, Foltzer C, Reimund J . Morphological and biochemical alterations in the jejunum following iodoacetamide-induced colitis in rats. Can J Physiol Pharmacol. 2007; 84(11):1191-203. DOI: 10.1139/y06-069. View

4.
Muza-Moons M, Schneeberger E, Hecht G . Enteropathogenic Escherichia coli infection leads to appearance of aberrant tight junctions strands in the lateral membrane of intestinal epithelial cells. Cell Microbiol. 2004; 6(8):783-93. DOI: 10.1111/j.1462-5822.2004.00404.x. View

5.
Jurjus A, Khoury N, Reimund J . Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods. 2004; 50(2):81-92. DOI: 10.1016/j.vascn.2003.12.002. View